Free androgen index as a predictor of blood pressure progression and accelerated vascular aging in menopause

Atherosclerosis

Volumn 247, Issue , 2016, Pages 177-183

  Georgiopoulos, Georgios A ^a   Lambrinoudaki, Irene ^b   Athanasouli, Fani ^a   Armeni, Eleni ^b   Rizos, Demetrios ^b   Kazani, Maria ^a   Karamanou, Marianna ^c   Manios, Efstathios ^a   Augoulea, Areti ^b   Stellos, Konstantinos ^d   Papamichael, Christos ^a   Stamatelopoulos, Kimon ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d GOETHE UNIVERSITY   (Germany)

Author keywords

Androgens; Arterial stiffness; FAI; Hemodynamics; Menopause

Indexed keywords

TESTOSTERONE; VASOACTIVE AGENT; ANDROGEN; BIOLOGICAL MARKER; HORMONE;

ADULT; AGING; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; DIASTOLIC BLOOD PRESSURE; ENDOTHELIUM; FLOW MEDIATED DILATION; FOLLOW UP; FREE ANDROGEN INDEX; HEMODYNAMICS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MENOPAUSE; POSTMENOPAUSE; PRIORITY JOURNAL; PULSE PRESSURE; PULSE WAVE; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; VASCULAR AGING; VASODILATATION; AGE; BLOOD; DISEASE COURSE; FEMALE; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; REGISTER; TIME FACTOR; VASCULAR ENDOTHELIUM;

AGE FACTORS; AGING; ANDROGENS; BIOMARKERS; BLOOD PRESSURE; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HORMONES; HUMANS; HYPERTENSION; MIDDLE AGED; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PULSE WAVE ANALYSIS; REGISTRIES; RISK FACTORS; TIME FACTORS; VASCULAR STIFFNESS;

EID: 84959036625     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.02.021     Document Type: Article

References (27)

1. Perk J., De Backer G., Gohlke H., Graham I., Reiner Z., Verschuren M., et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur. Heart J. 2012 Jul, 33(13):1635-1701.
2. Tunstall-Pedoe H. Myth and paradox of coronary risk and the menopause. Lancet 1998 May 9, 351(9113):1425-1427.
3. Ajani U.A., Ford E.S. Has the risk for coronary heart disease changed among U.S. adults?. J. Am. Coll. Cardiol. 2006 Sep 19, 48(6):1177-1182.
4. Lambrinoudaki I., Armeni E., Georgiopoulos G., Kazani M., Kouskouni E., Creatsa M., et al. Subclinical atherosclerosis in menopausal women with low to medium calculated cardiovascular risk. Int. J. Cardiol. 2013 Mar 20, 164(1):70-76.
5. Lambrinoudaki I., Christodoulakos G., Rizos D., Economou E., Argeitis J., Vlachou S., et al. Endogenous sex hormones and risk factors for atherosclerosis in healthy Greek postmenopausal women. Eur. J. Endocrinol. 2006 Jun, 154(6):907-916.
6. Patel S.M., Ratcliffe S.J., Reilly M.P., Weinstein R., Bhasin S., Blackman M.R., et al. Higher serum testosterone concentration in older women is associated with insulin resistance, metabolic syndrome, and cardiovascular disease. J. Clin. Endocrinol. Metab. 2009 Dec, 94(12):4776-4784.
7. Natoli A.K., Medley T.L., Ahimastos A.A., Drew B.G., Thearle D.J., Dilley R.J., et al. Sex steroids modulate human aortic smooth muscle cell matrix protein deposition and matrix metalloproteinase expression. Hypertension 2005 Nov, 46(5):1129-1134.
8. Reckelhoff J.F., Roman R.J. Androgens and hypertension: role in both males and females?. Hypertension 2011 Apr, 57(4):681-682.
9. Moulana M., Lima R., Reckelhoff J.F. Metabolic syndrome, androgens, and hypertension. Curr. Hypertens. Rep. 2011 Apr, 13(2):158-162.
10. Stamatelopoulos K., Sibbing D., Rallidis L.S., Georgiopoulos G., Stakos D., Braun S., et al. Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease. J. Am. Coll. Cardiol. 2015 Mar 10, 65(9):904-916.
11. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Bohm M., et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2013 Jul, 31(7):1281-1357.
12. Creatsa M., Armeni E., Stamatelopoulos K., Rizos D., Georgiopoulos G., Kazani M., et al. Circulating androgen levels are associated with subclinical atherosclerosis and arterial stiffness in healthy recently menopausal women. Metabolism 2012 Feb, 61(2):193-201.
13. Liu P.Y., Death A.K., Handelsman D.J. Androgens and cardiovascular disease. Endocr. Rev. 2003 Jun, 24(3):313-340.
14. McCrohon J.A., Jessup W., Handelsman D.J., Celermajer D.S. Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. Circulation 1999 May 4, 99(17):2317-2322.
15. Hutchison S.J., Sudhir K., Chou T.M., Sievers R.E., Zhu B.Q., Sun Y.P., et al. Testosterone worsens endothelial dysfunction associated with hypercholesterolemia and environmental tobacco smoke exposure in male rabbit aorta. J. Am. Coll. Cardiol. 1997 Mar 15, 29(4):800-807.
16. Bernini G.P., Moretti A., Sgro M., Argenio G.F., Barlascini C.O., Cristofani R., et al. Influence of endogenous androgens on carotid wall in postmenopausal women. Menopause 2001, 8(1):43-50.
17. Yanes L.L., Reckelhoff J.F. Postmenopausal hypertension. Am. J. Hypertens. 2011, 24(7):740-749.
18. Wang L., Szklo M., Folsom A.R., Cook N.R., Gapstur S.M., Ouyang P. Endogenous sex hormones, blood pressure change, and risk of hypertension in postmenopausal women: the multi-ethnic study of atherosclerosis. Atherosclerosis 2012, 224(1):228-234.
19. Armeni E., Stamatelopoulos K., Rizos D., Georgiopoulos G., Kazani M., Kazani A., et al. Arterial stiffness is increased in asymptomatic nondiabetic postmenopausal women with a polycystic ovary syndrome phenotype. J. Hypertens. 2013, 31(10):1998-2004.
20. Sabovic M., Safar M.E., Blacher J. Is there any additional prognostic value of central blood pressure wave forms beyond peripheral blood pressure?. Curr. Pharm. Des. 2009, 15(3):254-266.
21. Blacher J., Safar M.E., Guerin A.P., Pannier B., Marchais S.J., London G.M. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int. 2003, 63(5):1852-1860.
22. Laurent S., Briet M., Boutouyrie P. Large and small artery cross-talk and recent morbidity-mortality trials in hypertension. Hypertension 2009, 54(2):388-392.
23. Brandes R.P. Endothelial dysfunction and hypertension. Hypertension 2014, 64(5):924-928.
24. Singh H., Cheng J., Deng H., Kemp R., Ishizuka T., Nasjletti A., et al. Vascular cytochrome P450 4A expression and 20-hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgen-induced hypertension. Hypertension 2007, 50(1):123-129.
25. Chen J., Sowers M.R., Moran F.M., McConnell D.S., Gee N.A., Greendale G.A., et al. Circulating bioactive androgens in midlife women. J. Clin. Endocrinol. Metab. 2006, 91(11):4387-4394.
26. Baltatu O., Cayla C., Iliescu R., Andreev D., Bader M. Abolition of end-organ damage by antiandrogen treatment in female hypertensive transgenic rats. Hypertension 2003, 41(3 Pt 2):830-833.
27. Armanini D., Castello R., Scaroni C., Bonanni G., Faccini G., Pellati D., et al. Treatment of polycystic ovary syndrome with spironolactone plus licorice. Eur. J. Obstet. Gynecol. Reprod. Biol. 2007, 131(1):61-67.